Compared to non-combination therapies, the addition of PD-1/PD-L1 inhibitors to chemotherapy significantly prolonged OS in ESCC patients (I2 = 0%, HR: 0.68, 95% CI: 0.63-0.74). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.